Changes in gene expression in CD3+ T cells associated with disease progression in systemic lupus erythematosus (SLE) patients were determined. The genes related to SLE disease-related activities were identified and their gene regulatory networks were investigated. Analyses of gene expression were performed by both DNA microarray and real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression of certain genes including interferon (IFN) regulatory factor (IRF)-related genes, such as IFN-regulated, -related, and -signature genes was increased in the active phase of SLE. Pathway network analyses suggested that these IRF-related genes are regulated through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. JAK/STAT pathway-mediated regulation of IRF-related genes may have an important role in the disease activity of SLE. Inhibitors of JAK/STAT cascade may be useful as therapeutic agents.
SekigawaINaitoTHiraK. Possible mechanisms of gender bias in SLE: new hypothesis involving a comparison of SLE with atopy. Lupus2004; 13: 217–222.
2.
SekigawaIKawasakiMOgasawaraH. DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med2006; 6: 99–106.
3.
KawasakiMKanedaKKanekoHSekigawaITakasakiYOgawaH. Two cases of dermatomyositis associated with interstitial pneumonia: comprehensive study of gene expression. Clin Exp Rheumatol2008; 26: 79–380.
4.
KawasakiMSekigawaINozawaK. Changes in the gene expression of peripheral blood mononuclear cells during the menstrual cycle of females is associated with a gender bias in the incidence of systemic lupus erythematosus. Clin Exp Rheumatol2009; 27: 260–266.
5.
KawasakiMFujishiroMYamaguchiA. Fluctuations in the gene expression of peripheral blood mononuclear cells between the active and inactive phases of systemic lupus erythematosus. Clin Exp Rheumatol2010; 28: 311–317.
6.
QingXPuttermanC. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev2004; 3: 505–509.
7.
GladkevichANelemansAKauffmanHFKorfJ. Microarray profiling of lymphocytes in internal diseases with an altered immune response : potential and methodology. Mediators Inflamm2005; 6: 317–330.
8.
DaiYHuangYSTangM. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus2007; 16: 939–946.
9.
NakouMKnowltonNFrankMB. Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum2008; 58: 3541–3549.
10.
NikpourMDempseyAAUrowitzMBGladmanDDBarnesDA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis2008; 67: 1069–1075.
11.
LeeHMMimaTSuginoH. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther2009; 11: R1–R1.
12.
LiQZZhouJLianY. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol2010; 159: 281–291.
13.
TanENCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
14.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
15.
HaasCRyffelBLe HirM. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol1997; 158: 5484–5491.
16.
NicolettiFDi MarcoRZacconeP. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus like syndrome in MRL-lpr/lpr mice. Eur J Immunol2000; 30: 438–447.
17.
IoannouYIsenbergDA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum2000; 43: 1431–1442.
18.
MinDJChoMLChoCS. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol2001; 30: 159–163.
19.
Dall’eraMCCardarelliPMPrestonBTWitteADavis JrJC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis2005; 64: 1692–1697.
StrandbergLAmbrosiAEspinosaA. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol2008; 28: 220–231.
26.
MeineckeIPapGMendozaH. The small ubiquitin-like modifier mediates the resistance of prosthesis-loosening fibroblast-like synoviocytes against fas-induced apoptosis. Arthritis Rheum2009; 60: 2065–2070.
27.
KawagoeTTakeuchiOTakabatakeY. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol2009; 10: 965–972.
28.
EpinosaAZhouWEkM. The Sjogren,s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol2006; 176: 6277–6285.
29.
WadaKKamitaniT. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun2006; 339: 415–421.
30.
SabileAMeyerAMWirbelauerC. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol Cell Biol2006; 26: 5994–6004.
31.
KasperkovitzPVVerbeerNLSmeetsTJ. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis2004; 63: 233–239.
32.
CoombsJHBloomBJBreedveldFC. Improved pain, physical functional and health status in patients with rheumatoid arthritis treated with CP-690.550. an oral active janus kinase (JAK) inhibitor: Results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis2010; 69: 413–416.
33.
Quintas-CardamaAVaddiKLiuP. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood20103 February (Epub ahead of print).
